نتایج جستجو برای: recombinant tissue plasminogen activator rtpa

تعداد نتایج: 1042975  

2018
Shilpa Haldal Jonathan Beary Premkumar Nattanmai Pravin George Christopher Newey

The treatment of acute ischemic stroke is dependent on timely recognition. After ensuring airway, respiratory and circulatory stability, NIHSS should be performed and urgent CT scan obtained. If no exclusions exist, recombinant tissue plasminogen activator (rtPA) should be administered as soon as possible. Select patients may be eligible for mechanical thrombectomy. Stroke patients should be ad...

Manijhe Mokhtari-Dizaji Masoud Mehrpour Mosayyeb Mobasheri Tayebeh Toliyat

Introduction: Stroke causes death and disability in patients throughout the world. At present, the only FDA- approved drug for ischemic stroke is recombinant tissue plasminogen activator (rt- PA). Unfortunately, rtPA can cause intracerebral hemorrhage and must use within limited time window (within 3-4.5 hour after onset of stroke). Ultrasound with rtPA loaded liposomes (rtPA_L...

2016
Laurent Chazalviel Benoit Haelewyn Mickael Degoulet Jean-Eric Blatteau Nicolas Vallée Jean-Jacques Risso Stéphane Besnard Jacques H Abraini

Recent data have shown that normobaric oxygen (NBO) increases the catalytic and thrombolytic efficiency of recombinant tissue plasminogen activator (rtPA) in vitro, and is as efficient as rtPA at restoring cerebral blood flow in rats subjected to thromboembolic brain ischemia. Therefore, in the present study, we studied the effects of hyperbaric oxygen (HBO) (i) on rtPA-induced thrombolysis in ...

Journal: :iranian journal of allergy, asthma and immunology 0
afshin afshari r. elizbeth holme

the measurement of anti-streptokinase antibodies can distinguish the patients who may benefit from streptokinase and those who should be treated with some other thrombolytic regimen. neutralising titration test is a commonly used classical assay for measuring anti-streptokinase antibodies and in this assay the ability of anti-streptokinase antibodies in patients' sera in preventing the lytic ef...

Journal: :Stroke 2011
Clement Gakuba Maxime Gauberti Mikael Mazighi Gilles Defer Jean-Luc Hanouz Denis Vivien

BACKGROUND AND PURPOSE Endovascular treatment of ischemic stroke usually involves recombinant tissue-type plasminogen activator (rtPA)-mediated thrombolysis in anesthetized patients. Paradoxically, differential influences of anesthetic agents on thrombolysis outcome remain unknown. METHODS In situ thrombotic stroke was induced in mice by local injection of thrombin. Four hours after the ische...

Journal: :Stroke 2001
E Kilic M Bähr D M Hermann

BACKGROUND AND PURPOSE It has been suggested that recombinant tissue plasminogen activator (rtPA) may cause an aggravation of injury after transient focal ischemia via excitotoxic side effects. Such rtPA toxicity would be of major clinical significance since rtPA is increasingly used in stroke treatment. This study was conducted to evaluate the effects of dose, application time, and hemodynamic...

2016
Mei-Xue Dong Qing-Chuan Hu Peng Shen Jun-Xi Pan You-Dong Wei Yi-Yun Liu Yi-Fei Ren Zi-Hong Liang Hai-Yang Wang Li-Bo Zhao Peng Xie

BACKGROUND AND PURPOSE Recombinant tissue plasminogen activator (rtPA) is the only effective drug approved by US FDA to treat ischemic stroke, and it contains pleiotropic effects besides thrombolysis. We performed a meta-analysis to clarify effect of tissue plasminogen activator (tPA) on cerebral infarction besides its thrombolysis property in mechanical animal stroke. METHODS Relevant studie...

Journal: :The Journal of pharmacology and experimental therapeutics 2010
Ran Liu Qing Liu Shaoqing He James W Simpkins Shao-Hua Yang

Thrombolysis with recombinant tissue plasminogen activator (rtPA) in ischemic stroke is limited by the increased risk of hemorrhage transformation due to blood-brain barrier breakdown. We determined the interaction of 17beta-estradiol (E2) and rtPA on activation of plasminogen system and matrix metalloproteinases (MMPs) in a transient middle cerebral artery occlusion (MCAO) model. Ovariectomize...

Journal: :Medical research archives 2023

To demonstrate thrombolytic efficacy of a tissue plasminogen activator (tPA)-loaded echogenic liposome (TELIP) formulation in rabbit thrombotic stroke model (the most relevant animal for evaluation directed therapy ischemic stroke), we sought to develop means monitoring thrombus dissolution quantitatively by ultrasound imaging methods. We hypothesized that gas-free contrast agent can be incorpo...

Journal: :The Neurohospitalist 2015
Jennifer E Fugate Alejandro A Rabinstein

Most of the contraindications to the administration of intravenous (IV) recombinant tissue plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These were derived from expert consensus for the National Institute of Neurological Disorders and Stroke (NINDS) trial. Despite the fact that the safety and efficacy of IV rtPA has been repeatedly confirmed in large inte...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید